Загрузка...
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obta...
Сохранить в:
| Опубликовано в: : | Drug Des Devel Ther |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5633300/ https://ncbi.nlm.nih.gov/pubmed/29042751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S114932 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|